Sunflower Pharmaceutical Group Co.,Ltd
SZSE:002737.SZ
24 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,377.048 | 5,700.287 | 5,094.511 | 4,460.9 | 3,461.888 | 4,371.414 | 4,471.756 | 3,855.12 | 3,363.581 | 3,034.77 | 2,718.76 | 2,180.932 | 1,769.953 | 1,559.004 |
| Cost of Revenue
| 1,860.975 | 2,491.559 | 2,152.457 | 1,817.085 | 1,449.254 | 1,811.711 | 1,830.844 | 1,557.154 | 1,401.236 | 1,348.367 | 1,033.396 | 785.779 | 659.653 | 556.965 |
| Gross Profit
| 1,516.073 | 3,208.728 | 2,942.054 | 2,643.815 | 2,012.634 | 2,559.702 | 2,640.913 | 2,297.966 | 1,962.345 | 1,686.403 | 1,685.365 | 1,395.153 | 1,110.3 | 1,002.039 |
| Gross Profit Ratio
| 0.449 | 0.563 | 0.577 | 0.593 | 0.581 | 0.586 | 0.591 | 0.596 | 0.583 | 0.556 | 0.62 | 0.64 | 0.627 | 0.643 |
| Reseach & Development Expenses
| 113.38 | 118.5 | 103.195 | 139.276 | 119.376 | 121.676 | 125.54 | 106.836 | 66.484 | 40.834 | 23.153 | 26.516 | 27.066 | 10.831 |
| General & Administrative Expenses
| 116.364 | 116.605 | 130.723 | 117.25 | 80.342 | 112.469 | 113.866 | 115.304 | 113.303 | 84.012 | 56.879 | 44.896 | 44.546 | 53.128 |
| Selling & Marketing Expenses
| 251.532 | 1,128.591 | 1,274.274 | 1,175.498 | 872.949 | 1,276.747 | 1,447.095 | 1,277.048 | 1,171.206 | 1,025.733 | 993.386 | 814.672 | 600.126 | 560.325 |
| SG&A
| 367.896 | 1,834.771 | 1,404.997 | 1,292.748 | 953.291 | 1,389.215 | 1,560.961 | 1,392.352 | 1,284.509 | 1,109.745 | 1,050.266 | 859.568 | 644.672 | 613.453 |
| Other Expenses
| 387.804 | -111.369 | 322.963 | 351.223 | 157.87 | 271.409 | 4.657 | 9.656 | 80.225 | 61.968 | 23.863 | 39.715 | 28.521 | 35.094 |
| Operating Expenses
| 879.83 | 1,841.902 | 1,831.155 | 1,783.247 | 1,230.537 | 1,782.3 | 1,949.905 | 1,741.274 | 1,598.299 | 1,351.758 | 1,261.192 | 1,027.76 | 799.882 | 746.65 |
| Operating Income
| 636.243 | 1,366.826 | 1,084.99 | 885.203 | 766.622 | 760.412 | 715.746 | 555.066 | 343.113 | 340.514 | 383.404 | 307.854 | 264.502 | 220.996 |
| Operating Income Ratio
| 0.188 | 0.24 | 0.213 | 0.198 | 0.221 | 0.174 | 0.16 | 0.144 | 0.102 | 0.112 | 0.141 | 0.141 | 0.149 | 0.142 |
| Total Other Income Expenses Net
| -1.756 | -12.056 | -3.885 | 9.311 | 0.203 | 17.562 | 4.657 | 9.656 | 79.631 | 60.592 | 23.555 | 39.121 | 28.255 | 35.087 |
| Income Before Tax
| 634.488 | 1,354.77 | 1,081.105 | 894.514 | 766.825 | 777.974 | 720.403 | 564.722 | 422.332 | 401.106 | 406.959 | 346.975 | 292.757 | 256.083 |
| Income Before Tax Ratio
| 0.188 | 0.238 | 0.212 | 0.201 | 0.222 | 0.178 | 0.161 | 0.146 | 0.126 | 0.132 | 0.15 | 0.159 | 0.165 | 0.164 |
| Income Tax Expense
| 131.756 | 189.831 | 171.406 | 132.165 | 146.886 | 142.861 | 112.608 | 94.863 | 83.092 | 73.59 | 75.874 | 64.448 | 45.055 | 57.126 |
| Net Income
| 492.045 | 1,119.142 | 867.222 | 704.738 | 584.454 | 565.422 | 563.277 | 423.997 | 303.016 | 306.6 | 301.128 | 262.935 | 234.241 | 190.856 |
| Net Income Ratio
| 0.146 | 0.196 | 0.17 | 0.158 | 0.169 | 0.129 | 0.126 | 0.11 | 0.09 | 0.101 | 0.111 | 0.121 | 0.132 | 0.122 |
| EPS
| 0.84 | 1.92 | 1.48 | 1.21 | 1.01 | 0.97 | 0.96 | 0.73 | 0.52 | 0.53 | 0.69 | 0.6 | 0.54 | 0.44 |
| EPS Diluted
| 0.84 | 1.92 | 1.48 | 1.21 | 1.01 | 0.97 | 0.96 | 0.73 | 0.52 | 0.53 | 0.69 | 0.6 | 0.54 | 0.44 |
| EBITDA
| 819.087 | 1,546.867 | 1,363.14 | 1,075.688 | 923.374 | 941.248 | 873.004 | 720.895 | 569.31 | 511.299 | 512.952 | 450.589 | 421.369 | 391.458 |
| EBITDA Ratio
| 0.243 | 0.271 | 0.268 | 0.241 | 0.267 | 0.215 | 0.195 | 0.187 | 0.169 | 0.168 | 0.189 | 0.207 | 0.238 | 0.251 |